

Herantis Pharma will participate at Sachs 23rd Annual Biotech Forum and ØU Life Science Investor Conference in September 2023

Herantis Pharma Plc, Press Release 4 September 2023 at 17:10 EEST

Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, today announced that Herantis will participate in the following conferences in September 2023:

Sachs 23rd Annual Biotech in Europe Forum

Dates: September 20th - 21st, 2023

Location: Basel, Switzerland

1:1 meetings and company presentation.

CEO, Antti Vuolanto will participate in a panel discussion at Sachs, September 20th, 17:10 CEST.

Topic: Advances in Approaches to Neurological Disorders

Co-Chaired by:

Jenny Laird, VP, Search & Evaluation Neuroscience, Eli Lilly and Company

Henrik Sindal Jensen, Senior Director, Corporate Business Development & Strategy, H. Lundbeck A/S

ØU Life Science Investor Conference

Dates: September 27th, 2023

Location: Copenhagen, Denmark

CEO, Antti Vuolanto will give a company presentation at 14:05-14:35 CEST.

If you want a 1:1 meeting with Herantis, you can connect with us directly at ir@herantis.com.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDFN protein. It combines the compelling mechanism of action of the CDFN protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected in Q4-2023.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com